The Lancet· Domenica Lorusso, Jérôme Martin-Babau, Floor Backes, Maria Pilar Barretina Ginesta, Jacob Korach, Shibani Nicum, Julian Wampfler, Jianqing Zhu, Monika Ducceschi, Toon Van Gorp, Magnus Frödin-Bolling, Flora Zagouri, Judith R Kroep, Isabelle Ray-Coquard, Vanda Salutari, Michelle D S Lightfoot, Todd Tillmanns, David M O’Malley, Kosei Hasegawa, Jung-Yun Lee, Gonzalo H Giornelli, Vanessa Samouëlian, Yoland Antill, Jundong Li, Shin Nishio, Jack Junjie Chan, Bradley J Monk, Chenxiang Li, Kristina Woodhouse, Robert Orlowski, Carmen García-Duran, Bhavana Pothuri, TroFuse-005/ENGOT-en23/GOG-3095 Investigators·· 3 小时前评分77
TroFuse-005/ENGOT-en23/GOG-3095三期试验中sacituzumab tirumotecan较医生选择治疗改善晚期或复发子宫内膜癌PFS和OS
[Articles] Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial
导读
sacituzumab tirumotecan较医生选择治疗显著改善了晚期或复发子宫内膜癌患者的PFS和OS。TroFuse-005/ENGOT-en23/GOG-3095随机开放标签三期试验纳入已接受铂类化疗和免疫治疗的患者，原文据此支持将sac-TMT作为此类患者新的标准治疗。
来源：The Lancet · thelancet.com